公开(公告)号：US20190330369A1

公开(公告)日：2019-10-31

申请号：US16470032

申请日：2017-12-15

Applicant: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Inventor： Abdessatar Sami CHTOUROU ,  Nathalie FOURNIER ,  Christophe DE ROMEUF

IPC: C07K16/32 ,  C07K16/28 ,  A61P35/00

Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: a) at least one anti-CD303 antibody; and b) at least one anti-HER2 antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form combination products to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of HER2-positive cancer.